Mixed Data From Chelsea’s Northera Gets It No Closer To Approval
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Chelsea Therapeutics’ latest data release on its late-stage dizziness treatment for Parkinson’s patients raises new questions about the next steps for the drug.